Kyu Hong
Overview
Explore the profile of Kyu Hong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1573
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taylor M, Naing A, Powderly J, Woodard P, Chung L, Lin W, et al.
J Immunother Cancer
. 2024 Nov;
12(11).
PMID: 39567210
Purpose: In this first-in-human dose escalation study, the safety and efficacy of IO-108, a fully human monoclonal antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2), was investigated in patients with advanced...
2.
Sepah Y, Do D, Mesquida M, Day B, Blotner S, Afridi R, et al.
Eye (Lond)
. 2024 Apr;
38(9):1755-1761.
PMID: 38622330
Background: This analysis evaluated aqueous humour (AH) interleukin (IL)-6 concentrations and the association between AH IL-6 and visual outcomes in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular...
3.
Yu S, Lee D, Zheng B, Rosario G, Leipold D, Booler H, et al.
Mol Cancer Ther
. 2020 Dec;
20(2):340-346.
PMID: 33273056
We are interested in developing a second generation of antibody-drug conjugates (ADCs) for the treatment of non-Hodgkin lymphoma (NHL) that could provide a longer duration of response and be more...
4.
Cao Y, Guimaraes A, Peck M, Mayba O, Ruffin F, Hong K, et al.
Clin Transl Immunology
. 2020 Feb;
9(2):e1110.
PMID: 32082571
Objectives: To identify risk stratification biomarkers to enrich for the subset of bacteraemia patients who develop deep-seated tissue infections with high morbidity and mortality to guide clinical trial enrolment and...
5.
Carrasco-Triguero M, Dere R, Milojic-Blair M, Saad O, Nazzal D, Hong K, et al.
Bioanalysis
. 2019 Jun;
11(17):1555-1568.
PMID: 31208199
To evaluate the clinical immunogenicity of eight antibody-drug conjugates (ADCs), multi-domain biotherapeutics that could theoretically pose a greater immunogenicity risk than monoclonal antibodies (mAbs) because they contain non-natural structural motifs....
6.
Guimaraes A, Gutierrez J, Maskarinec S, Cao Y, Hong K, Ruffin F, et al.
Open Forum Infect Dis
. 2019 May;
6(4):ofz126.
PMID: 31041341
Background: is a leading global cause of bacteremia that can cause invasive tissue infections with high morbidity and mortality despite appropriate antibiotic therapy. Clinicians lack sufficient tools to rapidly identify...
7.
Stewart A, Krishnan A, Singhal S, Boccia R, Patel M, Niesvizky R, et al.
Blood Cancer J
. 2019 Feb;
9(2):17.
PMID: 30718503
FcRH5 is a cell surface marker enriched on malignant plasma cells when compared to other hematologic malignancies and normal tissues. DFRF4539A is an anti-FcRH5 antibody-drug conjugated to monomethyl auristatin E...
8.
Guimaraes A, Cao Y, Hong K, Mayba O, Peck M, Gutierrez J, et al.
Clin Infect Dis
. 2018 Aug;
68(9):1502-1511.
PMID: 30165412
Background: Staphylococcus aureus is a leading cause of bacteremia, yet there remains a significant knowledge gap in the identification of relevant biomarkers that predict clinical outcomes. Heterogeneity in the host...
9.
Wang-Lin S, Zhou C, Kamath A, Hong K, Koppada N, Saad O, et al.
MAbs
. 2018 Aug;
10(7):1131-1143.
PMID: 30081725
DSTA4637A, a THIOMAB™ antibody-antibiotic conjugate targeting Staphylococcus aureus, has shown promising bactericidal activity in a mouse model. DSTA4637A consists of a monoclonal anti-S. aureus antibody with an average of two...
10.
Fischer S, Carrasco-Triguero M, Hong K, Good J, Davancaze T, Nguy T, et al.
Bioanalysis
. 2016 Oct;
8(22):2351-2362.
PMID: 27704870
Aim: Commercial kits can provide a convenient solution for measuring circulating biomarkers to support drug development. However, their suitability should be assessed in the disease matrix of interest. Methodology: Twelve...